Literature DB >> 3875906

Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass.

N C Cavarocchi, H V Schaff, T A Orszulak, H A Homburger, W A Schnell, J R Pluth.   

Abstract

Complement activation by the alternate pathway has been implicated in the pathophysiology of cardiopulmonary bypass (CPB), and laboratory studies suggest that the complement cascade may be activated by the protamine-heparin complex. To determine if the administration of protamine to patients receiving heparin activates complement, we studied 100 patients undergoing CPB by assaying levels of C3a and C4a (classic pathway) at regular intervals before and after protamine administration. In group I (90 patients), protamine was given at the usual interval (median 5 minutes) after CPB. In group II (10 patients), protamine was withheld until skin closure (median 45 minutes) after CPB. Results demonstrated that C4a was not activated during CPB in either group. After CPB, the C4a level in group I was 459 ng/dl and increased to 1047 ng/dl 10 minutes after protamine administration (p less than 0.001). In group II, the C4a level was 484 ng/dl at the end of CPB and 354 ng/dl 15 minutes later, which corresponds to the value immediately after protamine administration in group I. The delayed administration of protamine in group II caused a significant increase in C4a at the time of skin closure (1090 ng/dl; p less than 0.001). Corresponding results from C3a analysis before and after protamine administration confirmed the activation of complement cascade. Our study provides the first clinical evidence that the protamine-heparin complex activates complement via the classic (C4a) pathway. The hemodynamic effects of protamine after CPB may be related to complement activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875906

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.

Authors:  L C Chang; J F Liang; H F Lee; L M Lee; V C Yang
Journal:  AAPS PharmSci       Date:  2001

2.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

3.  Complement activation during cardiac and thoracic vascular operations.

Authors:  P G Loubser
Journal:  Tex Heart Inst J       Date:  1987-12

Review 4.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  The observation of complement activation and polymorphonuclear neutrocytopenia during cardiopulmonary bypass.

Authors:  D Wang; P Fu; J Cai; H Lan
Journal:  J Tongji Med Univ       Date:  1996

Review 6.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

7.  The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution.

Authors:  F D Moore; K G Warner; S Assousa; C R Valeri; S F Khuri
Journal:  Ann Surg       Date:  1988-07       Impact factor: 12.969

8.  Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.

Authors:  L M Lee; L C Chang; S Wrobleski; T W Wakefield; V C Yang
Journal:  AAPS PharmSci       Date:  2001

9.  Carboxypeptidase N concentration during cardiopulmonary bypass in humans.

Authors:  S F Rabito; R Anders; W Soden; R A Skidgel
Journal:  Can J Anaesth       Date:  1992-01       Impact factor: 5.063

10.  Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.

Authors:  Mercedes Peleteiro; Elena Presas; Jose Vicente González-Aramundiz; Beatriz Sánchez-Correa; Rosana Simón-Vázquez; Noemi Csaba; María J Alonso; África González-Fernández
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.